(DARE) Daré Bioscience, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DARE) Daré Bioscience, Inc. Complete Analysis Pack
Don't Miss the Bigger Picture
This Daré Bioscience, Inc. Porter's Five Forces Analysis helps you quickly assess the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. This page already shows a real preview of the report, so you can review the content before buying. Purchase the full version for the complete ready-to-use analysis.
Suppliers Bargaining Power
Specialized raw material providers
In 2025, Daré Bioscience relied on a narrow pool of GMP-qualified API, excipient, and device-material suppliers, so any delay can hit development timelines fast. Women’s health products need tight dose, sterility, and device specs, which narrows the vendor base. That gives a hard-to-replace supplier real pricing power.
Switching can require new testing and regulatory re-qualification, so even 1 critical component can become a bottleneck. That raises Daré Bioscience’s cost risk and can squeeze margins if a qualified source is scarce.
Clinical trial and CRO services
Daré Bioscience, Inc. depends on CROs, labs, and trial-site networks to run studies, so these suppliers can set the pace on cost, timing, and protocol quality. That power is higher in niche women’s-health trials, where patient recruitment can consume up to 80% of trial timelines. When specialized sites are scarce, supplier leverage rises and Daré has less room to push fees down or speed up enrollment.
Manufacturing capacity constraints
Daré Bioscience relies on third-party manufacturers for development and future launch, so supplier power stays high. If a CDMO is full or prioritizes larger pharma customers, Daré can face higher unit costs and delayed slots, which is a real risk for sterile, hormone-based, and device-combination products. That can squeeze margins and slow commercialization when capacity is tight.
Intellectual property licensors
Daré Bioscience’s supplier power is high where a program relies on in-licensed patents or know-how, because licensors can demand better economics on unique science. That leverage shows up in royalty rates and milestone payments, which work like fixed supplier costs and can squeeze margins if a product advances slowly.
- In-licensed IP can control program access
- Unique science lifts licensor leverage
- Royalties and milestones raise deal cost
- Supplier power is highest per program
Low scale versus larger buyers
Daré Bioscience, Inc. is much smaller than major pharmaceutical buyers, so it places lower-volume orders and has less leverage on price, payment terms, and service levels. That weaker scale can make vendor contracts costlier than those of large peers, where bigger purchase baskets often win discounts and priority supply.
- Lower order volume cuts bargaining power
- Smaller scale can mean higher unit costs
- Supplier terms may be less favorable
Daré Bioscience Faces Heavy Supplier and Trial-Delay Risk
Daré Bioscience, Inc. faces high supplier power because its work depends on a narrow set of GMP suppliers, CDMOs, CROs, and licensors. In niche women’s-health trials, patient recruitment can consume up to 80% of trial timelines, and even 1 critical component can trigger re-qualification delays and higher costs.
| Risk driver | Data point | Impact |
|---|---|---|
| Trial recruitment | Up to 80% | Higher supplier leverage |
| Critical inputs | 1 component | Delay and re-test risk |
What is included in the product
Detailed Word Document
Tailored analysis of Daré Bioscience, Inc.’s competitive forces, supplier and buyer power, substitutes, and entry threats.
Customizable Excel Spreadsheet
A quick, one-page view of Daré Bioscience’s competitive pressures—ideal for faster strategic decisions.
Reference Sources
Provides a credible source trail for Daré Bioscience, Inc., helping decision-makers verify key claims quickly and trust the analysis.
Customers Bargaining Power
Prescribers shape demand
Physicians and other healthcare providers shape demand for Daré Bioscience, Inc.’s products because they decide what patients get. In women’s health, a single prescriber can affect adoption across many visits, so Daré has to prove safety, efficacy, and clear differentiation to win indirect buying power. That matters in a US prescription market where about 4.7 billion retail and mail-order prescriptions were filled in 2024.
Payers pressure pricing
Health plans, PBMs, and government payers can block uptake with formulary and reimbursement rules. In the U.S., about 66 million people are covered by Medicaid and Medicare serves more than 66 million, so payer terms matter fast. Even a strong clinical story can stall if coverage is narrow or prior auth is strict. That makes payer power high for Daré Bioscience, Inc.'s future launches.
Patients can switch easily
Patients can switch easily because women’s health products often compete on convenience, tolerability, and perceived value. Daré Bioscience, Inc. faces this in a market where even a modest cost gap matters: U.S. out-of-pocket drug spending was about $81 billion in 2023, so cheaper or easier options can pull users away fast. That keeps bargaining power with customers high and makes product experience a key driver of retention.
Organon as a commercial partner
Daré Bioscience, Inc.'s XACIATO sales depend on Organon, which paid Daré a $10 million upfront fee and holds U.S. commercialization rights, so one buyer-partner has outsized influence on economics. That can widen reach, but it also concentrates bargaining power in Organon if renewal, royalties, or launch support terms are reset. In Porter's terms, customer power is indirect here, yet still high because Daré's leverage hinges on one commercial counterparty.
- Single partner controls U.S. commercialization.
- $10 million upfront raised deal stakes.
- Daré's leverage depends on terms.
Concentrated near-term revenue base
Daré Bioscience, Inc. has a concentrated near-term revenue base, with limited marketed sales and a small commercial footprint, so it has few large customers today. That makes each buyer or channel partner more powerful on price, access, and contract terms. The company needs stronger product differentiation and a broader launch base to cut that dependence over time.
- Few customers, high buyer power
- Small footprint limits pricing leverage
- Differentiation can reduce dependence
Customer Power Is High for Daré Bioscience
Customer power is high for Daré Bioscience, Inc. because prescribers, payers, and patients can all slow uptake. XACIATO also adds concentration risk: Organon holds U.S. rights, so one partner can press hard on terms.
| Buyer | Power driver |
|---|---|
| Payers | 66M+ Medicare; ~66M Medicaid |
| Patients | $81B U.S. OOP drug spend, 2023 |
| Partner | Organon has U.S. rights |
Preview Before You Purchase
Daré Bioscience, Inc. Porter's Five Forces Analysis
This preview shows the exact Daré Bioscience, Inc. Porter’s Five Forces Analysis you’ll receive after purchase—no edits, no placeholders, and no surprises.
It’s the same professionally written, ready-to-use document, formatted for immediate download and use the moment your payment is complete.
What you see here is the final file, so you can buy with confidence knowing the full analysis will match this preview exactly.
Rivalry Among Competitors
Dense women’s health competition
Daré Bioscience competes in contraception, fertility, sexual health, and vaginal health, so its pipeline runs into crowded markets at once. Larger pharma, specialty biotech, and device makers already sell many of these products, which keeps pricing and differentiation pressure high. In women’s health, rivals often have far deeper sales reach and bigger R&D budgets, so rivalry is intense across every major pipeline category.
Large incumbents have scale
Large incumbents can outspend Daré Bioscience, Inc. on development, marketing, and physician education; Pfizer alone spent about $11.4 billion on R&D in 2025, while AbbVie spent over $9 billion. They also have deeper regulatory, commercial, and reimbursement teams, so Daré must fight firms with broader portfolios and stronger payer access.
Multiple product formats overlap
Daré’s programs compete with pills, rings, gels, creams, injectables, and non-hormonal methods, so rivalry cuts across several routes to the same outcome. That means the fight is not just inside one product class; it is across treatment formats. When multiple options aim at the same clinical goal, prescribers can switch fast, and pricing power stays weak.
Patent and lifecycle battles
Patent and lifecycle battles shape competitive rivalry for Daré Bioscience, Inc. because pharma wins come from IP, exclusivity, and clear user gains. A product can get 5 years of FDA new-chemical exclusivity, or 12 years if it is a biologic, so rivals often wait, challenge claims, or launch cleaner follow-ons.
That means Daré must defend patents, extend life with new data, and show better clinical or use benefits, not just a new label. If a rival offers easier dosing or lower friction, the moat can shrink fast.
- 5 years NCE exclusivity
- 12 years biologic exclusivity
- Patent defense is central
- Convenience can beat claims
Commercial success remains uncertain
Daré Bioscience’s rivalry is high because most of its pipeline is still in development, so it competes both for approval and for share after launch. In March 2024, the company reported cash and cash equivalents of about $24.9 million and a net loss of $41.2 million for 2023, showing limited room for long launch delays.
That risk is real: faster rivals can reach market first, and stronger clinical data can win prescribers and payers. For a small-cap biotech with no large commercial base, even one better-funded competitor can turn a promising asset into a weak one.
- Pipeline risk before approval
- Race to market matters most
- Better data can beat Daré
- Execution risk stays very high
Daré Faces Fierce Competition from Pharma Giants
Competitive rivalry is high for Daré Bioscience, Inc. because it faces large pharma and niche women’s-health rivals across contraception, fertility, sexual health, and vaginal health. Pfizer spent $11.4B on R&D in 2025, AbbVie $9.3B, so Daré meets better-funded players with deeper sales, data, and payer reach.
| Peer | 2025 R&D |
|---|---|
| Pfizer | $11.4B |
| AbbVie | $9.3B |
Substitutes Threaten
Existing standard therapies
Existing standard therapies keep the substitute threat high for Daré Bioscience, Inc., because patients can already use familiar options in women’s health. For bacterial vaginosis alone, the CDC says about 21 million U.S. women ages 14 to 49 are affected each year, and many can choose established antibiotics or other routine care. Contraception, hormone therapy, and sexual health also have deep incumbent options, so Daré’s pipeline must beat low-cost, proven treatments.
Non-drug solutions compete
In contraception and reproductive health, devices, behavioral methods, and procedures can replace drug-based products, so Daré Bioscience, Inc. faces real substitution pressure. Long-acting options like IUDs and implants already account for a large share of U.S. contraceptive use, and many patients still choose non-pharmaceutical methods for convenience or safety. If Daré’s products do not show clear benefits in efficacy, side effects, or ease of use, demand can stay limited.
Off-label and generic choices
Generics and off-label use are strong substitutes when they work clinically; in the U.S., generics fill about 90% of prescriptions but account for about 18% of drug spending, so price pressure is real. Price-sensitive patients and payers often choose the cheaper option first. Daré Bioscience, Inc. has to earn a premium with better convenience, safety, or outcomes.
Therapeutic class switching
Therapeutic class switching is a real threat for Daré Bioscience, Inc. because intimate-health users often leave a vaginal or hormone-based product if comfort, fit, or side effects are poor. In a category where adherence drives use, even small friction can push patients toward a different class, which weakens retention and pricing power.
This risk is sharper when the adoption barrier is user experience, not just efficacy, so the company must compete against non-vaginal and non-hormonal options as well. If the product feels inconvenient, a patient can switch classes quickly, making substitute pressure structurally high.
- Comfort and adherence drive switching risk.
Pipeline overlap with future innovation
Pipeline overlap is a real substitute risk for Daré Bioscience, Inc. because other firms are also pushing novel contraception and women’s health assets, and one better readout can make a current product look old fast. With FDA development still taking years and many assets failing before approval, Daré Bioscience, Inc. must keep clear clinical and user advantages or next-gen alternatives can take share.
- New rivals can reset demand fast
- Clinical proof drives substitution risk
- Daré Bioscience, Inc. needs clear differentiation
Daré Faces High Substitute Pressure in BV and Contraception
Threat of substitutes for Daré Bioscience, Inc. stays high because patients can switch to established drugs, devices, or non-hormonal methods with little friction. CDC data show about 21 million U.S. women ages 14 to 49 are affected by bacterial vaginosis each year, and long-acting contraceptives already hold a large share of use, so Daré needs clear gains in efficacy, safety, or convenience.
| Substitute pressure | Key data |
|---|---|
| BV standard care | 21M U.S. women yearly |
| Generic drugs | 90% of Rx, 18% of spend |
| Contraception | IUDs and implants are entrenched |
Entrants Threaten
High regulatory barriers
High regulatory barriers make entry hard in Daré Bioscience, Inc.'s market. A new drug usually needs Phase 1-3 trials and FDA review, which can take years and cost tens of millions, often far more. The FDA standard review clock is 10 months, or 6 months for priority review, so only firms with deep cash, trial know-how, and regulatory teams can compete.
Capital intensity deters entrants
Women’s health biopharma is capital heavy, so new entrants face a steep bar. Funding is needed for R&D, clinical validation, GMP manufacturing, and commercialization, and early-stage companies often stall before launch because cash burn outruns financing. For Daré Bioscience, Inc., this raises the entry hurdle and helps protect its niche.
IP and exclusivity barriers
Patents, trade secrets, and formulation know-how raise Daré Bioscience, Inc.'s entry barrier because they can block direct copycats and slow me-too rivals. That matters in its focused women's health areas, where even a small IP edge can protect pricing and time to market. Daré Bioscience, Inc.'s threat from new entrants stays lower when exclusivity is intact and enforced.
Trust and clinical credibility matter
Trust and clinical credibility raise the bar for any new entrant in women’s health, because physicians and payers usually wait for solid trial data and a clean safety record before they adopt a new therapy. Daré Bioscience, Inc. benefits here: in healthcare, trust takes years to build, while newcomers without validated clinical evidence face a slow, costly launch path.
- Physicians want proven safety.
- Payers want credible data.
- Validation speeds adoption.
- Trust is a long moat.
Specialized development know-how
Specialized development know-how raises the bar for new entrants in Daré Bioscience, Inc.'s niche. Intravaginal rings, topical formulations, and combination products need deep formulation, device, and clinical testing skills, plus tight quality control in manufacturing. That makes the field harder to enter than a plain-drug business, and it helps protect Daré Bioscience, Inc.'s position.
- Needs rare formulation expertise
- Requires device-plus-drug testing
- Manufacturing failures are costly
- Builds a moat for Daré Bioscience, Inc.
For a new company, the real hurdle is not just making a product, but proving it is stable, safe, and reproducible at scale. In practice, that slows entry, raises R&D spend, and gives established developers with prior product know-how a clear edge.
Daré’s Big Moat: High FDA Hurdles Keep New Entrants Out
Threat of new entrants is low for Daré Bioscience, Inc. because women’s health drug development needs years, heavy cash, and FDA proof before launch. In 2025, a standard FDA review still ran about 10 months, or 6 months with priority review. Deep IP, clinical data, and device-plus-drug know-how keep entry hard.
| Barrier | Current data |
|---|---|
| FDA review | 10 months; 6 priority |
| Development | Phase 1-3, years |
| Capital need | Often tens of millions |
| Moat | IP and clinical trust |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.